Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

Abstract Background KIT mutations are the predominant driver mutations in gastrointestinal stromal tumors (GISTs), and targeted therapy against KIT has improved treatment outcome dramatically. However, gaining secondary mutation of KIT confers drug resistance of GISTs leading to treatment failure. R...

Full description

Bibliographic Details
Main Authors: Guangrong Zhu, Jun Shi, Shaoting Zhang, Yue Guo, Ling Huang, Hui Zhao, Yideng Jiang, Jianmin Sun
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Cell & Bioscience
Subjects:
KIT
GISTs
PI3 kinase
Imatinib
Drug resistance
Online Access:https://doi.org/10.1186/s13578-020-0377-9

Internet

https://doi.org/10.1186/s13578-020-0377-9

Similar Items